Clinical Trials Logo

Papillary Thyroid Microcarcinoma clinical trials

View clinical trials related to Papillary Thyroid Microcarcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06333587 Recruiting - Clinical trials for Papillary Thyroid Microcarcinoma

Minimally Invasive Treatments of the Thyroid

MIPA-MITT
Start date: October 10, 2022
Phase:
Study type: Observational

This is a prospective cohort study to test Minimally Invasive Treatments of the Thyroid (MITT) as potential alternative to surgery in patients with Papillary Thyroid MicroCarcinoma (PTMC)

NCT ID: NCT05189821 Recruiting - Clinical trials for Papillary Thyroid Microcarcinoma

RFA Treatment for Papillary Thyroid Microcarcinoma

Start date: November 1, 2021
Phase:
Study type: Observational

Thyroid surgery has always been the mainstay of treatment for thyroid cancer. Thyroid surgery carries a low risk of complications that include recurrent or superior laryngeal nerve injury leading to voice changes, hypoparathyroidism, hypothyroidism with need for thyroid hormone supplementation, and unsightly scarring. Although many patients with thyroid cancer find these risks acceptable, these risks are sometimes less acceptable to patients with benign disease. In an era when the medical field is treating thyroid diseases less aggressively, there is a pressing need to identify approaches to treat indolent malignant disease less invasively. The purpose of this observational study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of Papillary Thyroid Microcarcinoma (PTMC) in patients that have already agreed to RFA procedure based on treating physician recommendation. This is a data collection study in which we ask participants to give us access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target tumor. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.

NCT ID: NCT04623801 Recruiting - Thyroid Cancer Clinical Trials

Laser Ablation of Papillary Thyroid Microcarcinoma

Start date: October 19, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.

NCT ID: NCT03808779 Recruiting - Clinical trials for Papillary Thyroid Microcarcinoma

A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

The treatment of Papillary Thyroid Microcarcinoma (PTMC) nowadays varies among physicians, surgeons and radiologist. The recently published articles show that the prognosis of PTMC by different means of treatment strategies tends to be good. But multicentered, randomized, parallel and prospective study is rare. RFA is the abbreviation of "Radiofrequency Ablation", which tends to be an alternative strategy except conventional surgery. The investigator aims to confirm whether RFA for treating PTMC braces same effectiveness and prognosis comparing with conventional surgery. Besides, this trial also investigates the safety, economy and psychological quality under different treatments.

NCT ID: NCT03432299 Recruiting - Thyroid Cancer Clinical Trials

Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma

RFAforPTMC
Start date: April 16, 2018
Phase: N/A
Study type: Interventional

This is a single center prospective clinical trial with regard to efficacy and safety of radiofrequency ablation of papillary thyroid microcarcinoma.

NCT ID: NCT02609685 Recruiting - Clinical trials for Papillary Thyroid Microcarcinoma

Active Surveillance of Papillary Thyroid Microcarcinoma

PMCAS
Start date: May 13, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.